AGB101

DRUG3 trials

Sponsors

Johns Hopkins University, AgeneBio

Conditions

DementiaHippocampal OveractivityMild Cognitive ImpairmentParkinson Disease PsychosisProdromal Alzheimer's Disease

Phase 2

Clinical Trial Evaluating the Efficacy and Safety of AGB101 for Treatment of Parkinson's Disease Related Psychosis

RecruitingNCT05824728

Johns Hopkins UniversityParkinson Disease Psychosis

Start: 2023-09-28End: 2026-12-01Target: 30Updated: 2026-09-03

Clinical Trial of AGB101 for Mild Cognitive Impairment

WithdrawnNCT05986721

AgeneBioMild Cognitive Impairment, Prodromal Alzheimer's Disease

Start: 2024-12-03End: 2028-12-31Updated: 2025-05-25

Clinical Trial Evaluating the Efficacy of AGB101 for Reducing Hippocampal Overactivity in Older Adults

Active, not recruitingNCT06919926

Johns Hopkins UniversityDementia, Hippocampal Overactivity

Start: 2025-04-17End: 2028-05-01Target: 60Updated: 2026-08-31